By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


 

Novo Nordisk A/S 

Novo Allé

Bagsvaerd    2880  Denmark
Phone: 45-4444-8888 Fax: 45-4449-0555


SEARCH JOBS

Novo Nordisk is a global healthcare company with more than 90 years of innovation and leadership in diabetes care.

YEAR FOUNDED:

1922

LEADERSHIP:

Founders: August Krogh and Marie Krogh

CEO: Lars Rebien Sørensen

CFO: Jesper Brandgaard

CSO (Scientific): Mads Krosgsgaard Themsen

JOBS:

Please click here for Novo Nordisk job opportunities.

CLINICAL TRIAL:

Please click here for clinical trial information.

FOLLOW NOVO NORDISK:




Key Statistics


Email:
Ownership: Public

Web Site: Novo Nordisk A/S
Employees: 13395
Symbol: NVO
 



Industry
Big Pharma


Collaborations

CelTor Biosystems, Inc.  Research collaboration

Aradigm  Commercial agreement to develop AERx technology for the delivery of insulin, insulin analogues and other glucose-lowering agents for diabetes management.

Maxygen, Inc. 

Intergen Company 





Company News
Novo Nordisk A/S (NVO): CHMP Adopts Positive Opinion For EU Label Update Of Victoza Based On The LEADER Trial 6/23/2017 8:14:18 AM
Novo Nordisk A/S (NVO) Receives Positive 17-2 Vote From FDA Advisory Committee That Victoza Provides Substantial Evidence Of Cardiovascular Risk Reduction In Patients With Type 2 Diabetes 6/21/2017 7:29:18 AM
Novo Nordisk A/S (NVO) - Share Repurchase Programme 6/19/2017 7:23:02 AM
Life Sciences Professionals Name Top 30 Ideal Employers 6/15/2017 10:43:10 AM
Novo Nordisk A/S (NVO) Release: Tresiba Demonstrated No Increased Risk Of Major Cardiovascular Events And Significant Reduction In Rates Of Severe Hypoglycaemia Compared To Insulin Glargine U100 In The DEVOTE Trial 6/13/2017 6:34:50 AM
Novo Nordisk A/S (NVO) Release: Xultophy 100/3.6 Demonstrated Similar A1C Reductions With Significantly Lower Rates Of Hypoglycemia And A Decrease In Weight Vs Basal-Bolus Therapy 6/12/2017 7:03:53 AM
Novo Nordisk A/S (NVO) Release: Tresiba Demonstrated No Increased Risk Of Major Cardiovascular Events And Significant Reduction In Rates Of Severe Hypoglycaemia Compared To Insulin Glargine U100 In The DEVOTE Trial 6/9/2017 10:36:16 AM
Novo Nordisk A/S (NVO) - Share Repurchase Programme 6/6/2017 7:31:11 AM
Innate Pharma (IPH.PA ) Regroups From Trial Failure With €410 Million Deal For Novo Nordisk A/S (NVO)'s AntiC5aR Antibody 6/5/2017 6:33:35 AM
FDA Approves New Novo Nordisk A/S (NVO) Treatment For Patients With Hemophilia 6/1/2017 6:51:59 AM
12345678910...
//-->